Fobeni Healthcom Pharmaceutical Jiangsu

Fobeni Healthcom Pharmaceutical Jiangsu is a joint venture established in 2018 by Shanghai Fosun Pharmaceutical and Marubeni Corporation. Headquartered in Taizhou, China, the company serves as a strategic bridge for Japanese pharmaceutical firms to navigate the Chinese market, providing services in regulatory compliance, drug approval, and distribution. Its clinical pipeline is highlighted by nacubactam (OP0595), a novel beta-lactamase inhibitor currently in Phase 3 trials for treating multi-drug resistant infections. Additionally, Fobeni has expanded into the consumer health sector with products like the WASLIM GLP-1 compound drink for weight management. The company leverages Fosun's extensive sales network and Marubeni's global reach to commercialize innovative therapies across China and potentially international markets.